

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

accept change(s) to the agreed paediatric investigation plan

MHRA-100143-PIP01-21-M01

### **Scope of the Application**

#### **Active Substance(s)**

TENOFOVIR ALAFENAMIDE FUMARATE

#### **Condition(s)**

Treatment of chronic viral hepatitis B

#### **Pharmaceutical Form(s)**

Film-coated tablet; Age-appropriate non-tablet formulation

#### **Route(s) of Administration**

Oral use

### **Name / Corporate name of the PIP applicant**

Gilead Sciences Ltd

### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, Gilead Sciences Ltd submitted to the licensing authority on 04/06/2021 17:12 BST an application for a Modification

The procedure started on 22/04/2022 07:51 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom  
[gov.uk/mhra](https://gov.uk/mhra)

## Final Decision Letter

MHRA-100143-PIP01-21-M01

Of 27/05/2022 06:51 BST

On the adopted decision for TENOFOVIR ALAFENAMIDE FUMARATE (MHRA-100143-PIP01-21-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for TENOFOVIR ALAFENAMIDE FUMARATE, Film-coated tablet; Age-appropriate non-tablet formulation , Oral use .

This decision is addressed to Gilead Sciences Ltd, 280 High Holborn, London, United Kingdom, WC1V 7EE

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Treatment of chronic viral hepatitis B The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 2 years of age Pharmaceutical form(s): Film-coated tablet; Age appropriate non-tablet formulation Route(s) of administration: Oral use Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Treatment of chronic viral hepatitis B

**2.2 Indication(s) targeted by the PIP:**

Treatment of chronic hepatitis B infection

**2.3 Subset(s) of the paediatric population concerned by the paediatric development:**

The paediatric population from 2 years to less than 18 years of age

**2.4 Pharmaceutical Form(s):**

Film-coated tablet; Age appropriate non-tablet formulation

**2.5 Studies:**

<b>Study Type</b>	<b>Number of Studies</b>	<b>Study Description</b>
<b>Quality Measures</b>	1	Study 1 Deleted during procedure MHRA-100143-PIP01-21-M01 Study 2 Development of an age appropriate oral non-tablet formulation.
<b>Non-Clinical Studies</b>	0	Not applicable
<b>Clinical Studies</b>	2	Study 3 deleted during procedure EMEA-001584-PIP01-13-M02 Study 4 (Cohort 2 of GS-US-320-1092) Double-blind, placebo-controlled, pharmacokinetic, efficacy, safety, tolerability and antiviral activity study of tenofovir alafenamide administered for 24 weeks followed by 24 weeks open label extension phase in treatment naïve and treatment experienced, HBeAg-positive and HBeAg-negative children (2 years to less than 12 years of age) with chronic hepatitis B infection. Study 5 (GSUS-320-1196) Open-label, relative bioavailability study of the proposed age-appropriate paediatric formulation in healthy adult volunteers.
<b>Extrapolation, Modeling &amp; Simulation Studies</b>	0	Not applicable
<b>Other Studies</b>	0	Not applicable
<b>Other Measures</b>	0	Not applicable

**3. Follow-up, completion and deferral of a PIP:**

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	Yes
<b>Date of completion of the paediatric investigation plan:</b>	30/09/2023
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes